Clinical Trial Update: Ampyra for Optic Neuritis in Multiple Sclerosis [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial update for Ampyra in optic neuritis associated with multiple sclerosis; results have been posted following completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Optic Neuritis

Drugs mentioned

• Ampyra (4-aminopyridine)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Multiple Sclerosis, Optic Neuritis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-01-30